Blockchain Registration Transaction Record

GeoVax Advances Mpox/Smallpox Vaccine Toward Global Stockpiles in Strategic Shift

GeoVax initiates global procurement talks for GEO-MVA mpox/smallpox vaccine candidate, aiming to diversify MVA vaccine supply through expedited Phase 3 study starting 2026.

This development matters because it addresses critical vulnerabilities in global health security. With mpox now recognized as a recurring threat rather than a one-time outbreak, and smallpox remaining a bioterrorism concern, the world's reliance on a single manufacturer for MVA vaccines creates dangerous supply chain fragility. GeoVax's GEO-MVA candidate represents a crucial diversification effort that could strengthen national stockpiles, military readiness, and outbreak response capabilities. For the public, this means better protection against potential health emergencies, while for governments and health organizations, it offers strategic redundancy in medical countermeasures. The expedited regulatory pathway and engagement with procurement agencies signal that GEO-MVA could soon become an operational asset in the global preparedness arsenal, potentially preventing the vaccine shortages that hampered early mpox response efforts.